Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
Interventions: PD-0332991; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: irofulven; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Parkinson's Disease
Interventions: Activa PC+S; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sedentary Lifestyle
Interventions: Virtual Advisor, Promotora for physical activity; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 50 Years and older
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Autism Spectrum Disorders
Interventions: No intervention; Other
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 4 Years to 18 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Antiphospholipid Syndrome
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Not listed
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 7
States / cities: Atlanta, Georgia • Baltimore, Maryland • New York, New York + 4 more

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Obstructive Sleep Apnea
Interventions: Transoral robotic surgery (TORS); Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Aphasia
Interventions: Language therapy, Background Music, Aerobic Exercise; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan MR, Tolvaptan IR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more

Conditions: Hemorrhagic Stroke, Ischemic Stroke
Interventions: SENSE Device; Device
Lead sponsor: Sense Diagnostics, LLC; Industry
Eligibility: 22 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine formulation: liquid vs. tablet; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1999
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcoma
Interventions: cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna; Drug · Procedure · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 40 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 77
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more

Conditions: Stage I Prostate Cancer, Stage II Prostate Carcinoma
Interventions: Visualase Thermal Therapy, magnetic resonance imaging; Device · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 45 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dravet Syndrome (DS)
Interventions: Soticlestat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more

Conditions: Leukemia, Lymphoma
Interventions: Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypoglycemia
Interventions: Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Osteoarthritis
Interventions: Exercise Training; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 40 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hookah Smoking
Interventions: Hookah tobacco risk messages; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Durham, North Carolina

Conditions: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: TAS-102, Placebo; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Healthy
Interventions: Placebo, JNJ-41443532; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

Neural Signatures of Parkinson's Disease

Virtual Advisors for Physical Activity Promotion in Underserved Communities

Investigating Phenotypic Profiles of Children and Adolescents With ASD

Antiphospholipid Syndrome Collaborative Registry (APSCORE)

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Transoral Robotic Surgery (TORS) for Sleep Apnea

Aerobic Exercise and Aphasia Treatment

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Early Feasibility Study of the SENSE Device

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

G-Pen™ for Hypoglycemia Rescue in T1D Patients

Regular Swimming, Vascular Function, and Arthritis

Optimizing Risk Messages for Waterpipe Tobacco Cessation in Young Adults

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study